ERBB2 and gastric cancer: In June 2021, the National Medical Products Administration granted approval for RC48 as a treatment for patients with locally progressive or metastatic GC (including gastric junction adenocarcinoma) who exhibit HER2 overexpression and have undergone at least two rounds of systemic chemotherapy [98].